CN114561372B - Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌 - Google Patents

Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌 Download PDF

Info

Publication number
CN114561372B
CN114561372B CN202210447410.5A CN202210447410A CN114561372B CN 114561372 B CN114561372 B CN 114561372B CN 202210447410 A CN202210447410 A CN 202210447410A CN 114561372 B CN114561372 B CN 114561372B
Authority
CN
China
Prior art keywords
leu
ala
glu
lys
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210447410.5A
Other languages
English (en)
Other versions
CN114561372A (zh
Inventor
刁含文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jujiang Biotechnology Co ltd
Original Assignee
Nanjing Jujiang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jujiang Biotechnology Co ltd filed Critical Nanjing Jujiang Biotechnology Co ltd
Priority to CN202210447410.5A priority Critical patent/CN114561372B/zh
Publication of CN114561372A publication Critical patent/CN114561372A/zh
Application granted granted Critical
Publication of CN114561372B publication Critical patent/CN114561372B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1252DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07007DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/101Plasmid DNA for bacteria
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明提供了一种Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌,涉及生物技术领域。本发明提供的Bst DNA聚合酶突变体,将野生型Bst DNA聚合酶的第370位的Met突变为Gly,第444位的Ala突变为Gly。该Bst DNA聚合酶突变体热稳定性好,非特异性扩增反应减少,重复性好,能够应用于环介导等温扩增技术中。

Description

Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基 因工程菌
技术领域
本发明涉及生物技术领域,尤其是涉及一种Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌。
背景技术
DNA聚合酶自发现起始就获得了生物医学界的广泛关注,因此也被广泛应用。BstDNA聚合酶(Bst DNA polymerase)由E.coli菌株产生,含有来自Bacillusstearothermophilus DNA 聚合酶的基因,该基因缺失了5'→3'外切核酸酶结构域,但有5'→3'DNA聚合酶活性,不具有5'→3'外切核酸酶活性。Bst DNA聚合酶具有较强的热稳定性和链置换活性,被广泛地用于富含GC碱基对的DNA测序、纳克级含量DNA模板的快速测序、DNA的等温扩增、多重链置换扩增(multiple displacement amplifi-cation,MDA)和全基因组扩增 (whole genome amplification,WGA)。此外,Bst DNA聚合酶还能启动模板依赖的DNA合成,在3'末端随机添加核苷酸。以Bst DNA聚合酶为基础而开发的核酸等温扩增检测技术得到了迅猛的发展,正逐步在分子生物学、医学、法学、食品检验领域广泛应用.目前,以Bst DNA聚合酶为基础的核酸等温扩增检测技术应用较多的是滚环扩增(rollingcircle amplifi-cation,RCA)技术和环介导等温扩增(loop-mediated isothermalamplification,LAMP)技术。滚环扩增技术具有特异性强、灵敏度高、快速简便以及高通量测定等特点而被广泛应用,但是由于在检测过程中出现背景信号,给该方法的应用带来了一定的局限性。虽然研究人员尽可能采取措施减少背景信号的出现,降低其对检测的影响,却未能彻底解决该问题,也未能对背景信号产生的机理解释楚。LAMP技术是日本学者Notomi在2000年发明的,他利用特殊的引物设计方法和恒温核酸链置换酶,可以在60分钟内,将少量目标DNA扩增到千百万份。目前该技术应用已经有超过20年的历史。LAMP技术是一种新型的核酸扩增方法,其特点是针对靶基因的6-8个区域设计4-6种特异引物,进行高度特异性扩增反应。在链置换酶Bst DNA聚合酶的作用下,与特殊设计的引物形成环结构,在60~65℃进行恒温扩增,大约15~60min可实现109~1010倍的核酸扩增,具有操作简单。LAMP反应温度一般在65℃,扩增程度小于250nt。DNA产物非常长,大于20KB,由80–250bp的短目标序列多次重复形成,与长链共聚体中的单链环区相连。这些产品通常不适合下游操作,但目标扩增非常的多,因此有可能有多种检测模式。采用插层或探针、横向流动和琼脂糖凝胶检测等方法的实时荧光检测均与LAMP反应直接兼容。LAMP设备通常需要加热到所需反应温度,并在需要时实时荧光进行定量测量。该技术不依赖任何专门的贵重仪器设备,具有简单、快速、特异性强的特点,能够媲美甚至优于PCR技术,而检测成本远低于荧光定量PCR。但是,LAMP技术的最大缺陷是容易产生非特异性扩增反应,非特异性扩增反应发生的原因还未见明确的报道。
有鉴于此,特提出本发明。
发明内容
本发明的第一目的在于提供一种Bst DNA聚合酶突变体,以解决上述问题中的至少一种。
本发明的第二目的在于提供上述Bst DNA聚合酶突变体在制备环介导等温扩增产品中的应用。
本发明的第三目的在于提供一种环介导等温扩增产品。
本发明的第四目的在于提供一种基因,该基因编码上述Bst DNA聚合酶突变体。
本发明的第五目的在于提供一种重组质粒。
本发明的第六目的在于提供一种基因工程菌。
第一方面,本发明提供了一种Bst DNA聚合酶突变体,所述Bst DNA聚合酶突变体的氨基酸序列如SEQ ID NO.1所示。
作为进一步技术方案,所述Bst DNA聚合酶突变体的核苷酸序列如SEQ ID NO.2所示。
第二方面,本发明提供了上述Bst DNA聚合酶突变体在制备环介导等温扩增产品中的应用。
第三方面,本发明提供了一种环介导等温扩增产品,包括上述Bst DNA聚合酶突变体。
第四方面,本发明提供了一种基因,所述基因编码上述Bst DNA聚合酶突变体。
作为进一步技术方案,所述基因具有SEQ ID NO.2所示的核苷酸序列。
第五方面,本发明提供了一种重组质粒,所述重组质粒包括载体和上述基因。
作为进一步技术方案,所述载体包括pET-24a(+)质粒。
第六方面,本发明提供了一种基因工程菌,所述基因工程菌含有上述重组质粒。
作为进一步技术方案,所述基因工程菌包括大肠杆菌。
与现有技术相比,本发明具有如下有益效果:
本发明提供的Bst DNA聚合酶突变体,将野生型Bst DNA聚合酶的第370位的Met突变为Gly,第444位的Ala突变为Gly。该Bst DNA聚合酶突变体热稳定性好,非特异性扩增反应减少,重复性好,能够应用于环介导等温扩增技术中。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为野生型Bst DNA聚合酶的构象分析;
图2为BstMut在LAMP不同温度条件下的结果对比;
图3为实施例3的扩增结果。
具体实施方式
下面将结合实施方式和实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施方式和实施例仅用于说明本发明,而不应视为限制本发明的范围。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
第一方面,本发明提供了一种Bst DNA聚合酶突变体,所述Bst DNA聚合酶突变体的氨基酸序列如SEQ ID NO.1所示:
MKKKLVLIDGNSVAYRAFFALPLLHNDKGIHTNAVYGFTMMLNKILAEEQPTHLLVAFDAGKTTFRHETFQEYKGGRQQTPPELSEQFPLLRELLKAYRIPAYELDHYEADDIIGTLAARAEQEGFEVKIISGDRDLTQLASRHVTVDITKKGITDIEPYTPETVREKYGLTPEQIVDLKGLMGDKSDNIPGVPGIGEKTAVKLLKQFGTVENVLASIDEVKGEKLKENLRQHRDLALLSKQLASICRDAPVELSLDDIVYEGQDREKVIALFKELGFQSFLEKMAAPAAEGEKPLEEMEFAIVDVITEEMLADKAALVVEVMEENYHDAPIVGIALVNEHGRFFMRPETALADSQFLAWLADETKKKSGFDAKRAVVALKWKGIELRGVAFDLLLAAYLLNPAQDAGDIAAVAKMKQYEAVRSDEAVYGKGVKRSLPDEQTLGEHLVRKAAAIWALEQPFMDDLRNNEQDQLLTKLEQPLAAILAEMEFTGVNVDTKRLEQMGSELAEQLRAIEQRIYELAGQEFNINSPKQLGVILFEKLQLPVLKKTKTGYSTSADVLEKLAPHHEIVENILHYRQLGKLQSTYIEGLLKVVRPDTGKVHTMFNQALTQTGRLSSAEPNLQNIPIRLEEGRKIRQAFVPSEPDWLIFAADYSQIELRVLAHIADDDNLIEAFQRDLDIHTKTAMDIFHVSEEEVTANMRRQAKAVNFGIVYGISDYGLAQNLNITRKEAAEFIERYFASFPGVKQYMENIVQEAKQKGYVTTLLHRRRYLPDITSRNFNVRSFAERTAMNTPIQGSAADIIKKAMIDLAARLKEEQLQARLLLQVHDELILEAPKEEIERLCELVPEVMEQAVTLRVPLKVDYHYGPTWYDAK(SEQ ID NO.1)。
本发明首先基于野生型Bst DNA聚合酶的原始氨基酸序列进行理性设计(SwissModel建模分析)分析其构象差异,如图1所示,对于其易变区的Met370位点以及Ala444位点进行突变为Gly,提高了Bst DNA聚合酶的热稳定性,同时提升了Bst在LAMP法中的使用效果。其中野生型Bst DNA聚合酶的氨基酸序列如SEQ ID NO.3所示:
MKKKLVLIDGNSVAYRAFFALPLLHNDKGIHTNAVYGFTMMLNKILAEEQPTHLLVAFDAGKTTFRHETFQEYKGGRQQTPPELSEQFPLLRELLKAYRIPAYELDHYEADDIIGTLAARAEQEGFEVKIISGDRDLTQLASRHVTVDITKKGITDIEPYTPETVREKYGLTPEQIVDLKGLMGDKSDNIPGVPGIGEKTAVKLLKQFGTVENVLASIDEVKGEKLKENLRQHRDLALLSKQLASICRDAPVELSLDDIVYEGQDREKVIALFKELGFQSFLEKMAAPAAEGEKPLEEMEFAIVDVITEEMLADKAALVVEVMEENYHDAPIVGIALVNEHGRFFMRPETALADSQFLAWLADETKKKSMFDAKRAVVALKWKGIELRGVAFDLLLAAYLLNPAQDAGDIAAVAKMKQYEAVRSDEAVYGKGVKRSLPDEQTLAEHLVRKAAAIWALEQPFMDDLRNNEQDQLLTKLEQPLAAILAEMEFTGVNVDTKRLEQMGSELAEQLRAIEQRIYELAGQEFNINSPKQLGVILFEKLQLPVLKKTKTGYSTSADVLEKLAPHHEIVENILHYRQLGKLQSTYIEGLLKVVRPDTGKVHTMFNQALTQTGRLSSAEPNLQNIPIRLEEGRKIRQAFVPSEPDWLIFAADYSQIELRVLAHIADDDNLIEAFQRDLDIHTKTAMDIFHVSEEEVTANMRRQAKAVNFGIVYGISDYGLAQNLNITRKEAAEFIERYFASFPGVKQYMENIVQEAKQKGYVTTLLHRRRYLPDITSRNFNVRSFAERTAMNTPIQGSAADIIKKAMIDLAARLKEEQLQARLLLQVHDELILEAPKEEIERLCELVPEVMEQAVTLRVPLKVDYHYGPTWYDAK(SEQ ID NO.3)。
在一些优选的实施方式中,所述Bst DNA聚合酶突变体的核苷酸序列如SEQ IDNO.2所示:
ATGAAAAAGAAATTAGTTTTGATTGATGGTAATTCTGTCGCTTATCGTGCCTTTTTCGCACTTCCTCTCCTACATTCCGACAAGGGCATCCACACTAACGCGGTATACGGATTTACCATGATGCTGATGAAAATATTAGAAGAGGAAAAGCCCACACATATGTTGGTGGCTTTCGATGCCGGGAAAACGACTTTTCGCCACAAGACCTTCGAGGAATATAAAGGTGGCCGACAAAAGACACCACCGGAGCTTTCAGAACAGTTTCCTCTCCTACGGGAGCTGTTAAATGCATACCAAATTAGATTCTATGAATTGGAGAACTACGAAGCGGACGATATCATAGGAACGCTTTGTACTAAAGCTGAGAATGCCGGGTTTGAAGTTAAGGTCATTTCGGGTGACAGGGATCTCACCCAGCTAGCAAGTGACCATGTAACAGTGGATATCACGAAAAAGGGCATAACTGACGTTGAGAGCTATACCCCCGAAACAGTCCGTGAGAAATACGGACTGACGCCAAAGCAAATTATCGATTTAAAAGGGTTGATGGGTGACAAGTCTGATAACATACCGGGCGTACCTGGAATTGGGGAAAAAACTGCGCTTAAGCTCCTAAAAGAGTTCGGTACCATCGAAAATATACTGGACTCCTTAGAGCAGATTTCAGGCAACAAGTTGAAAGAAAATCTTGCTAAGTATCGCGATCTCGCCATCATGTCGAAACAACTAGCAACAATACTGCGAGACGCGCCCATTGATTTAAGTTTGGAGGACATCGAATACCGGGGATATGATGCTGACAAGGTGATAGCCCTTTTTAAAGAGCTCGGGTTCAACAGCCTACTGGATAAGATGGCACCAAGAGAAGAGGAAAAAGCGGGTGTTGTCTTACCGAAGATTGGCTACACGATCGTAGACGAGGTGACTGAAGCTATATTGTCTGATGAGGCCGCACTTGTTGTCGAAGTACTCGAGTCCAATTATCACAAAGCGCCTATTCTAGGATTTGCTATCGCCAACGAACATGGGAATTTCTTTATAAGGACCGACACAGCACTGTCATCGAGTTTATTCACGGCGTGGTTGGAGGATGAAAGCAAGAAAAAGGGTGTGTTTGACGGTAAACGTGCTATTGTTTCCCTTAAGTGGCAGGGCGTCCAACTCCGCGGAATCCAGTTCGATCTACTGATAGCCTCATACTTATTGAACCCCTCGCAAAGTACTGAGGACGTAGCAAGCATTGCGAAAACCAAGCAGTATACAGGGGTGCAACCAGATGAAGCTGTTTACGGTAAAGGCGCCAAGCAGAAAATCCCGGACGAGCAAGTCCTTGGAGAACACCTCGTACGAAAGGCGGCTGCCATACGGGCACTAGAGCAGGATTTTATTCATGACCTGCAAGAAAATGAGCAGTATTCTTTATTCACGGATTTGGAACTTCCTCTCTCCGCGATCCTAGCTGAGATGGAATTTACTGGAGTGAAAGTTGACGTCAAGAGACTGAAAGAGATGGGGGAAGAGTTAACCGAACAATTGAAGGAGGTAGAACAGGAGATATACAGGCTTGCCGGTCAAGAATTCAACATTAATTCACCCAAACAGCTCGGCGTGATCCTATTTGAGAAGCTGCAATTACCAGTTTTGAAAAAGACAAAAACGGGATATTCGACTAGTGCAGAAGTCCTTGAGAAGCTCGCGCCGCAGCACGAAATAGTAGAGAAAATTCTACATTACCGTCAACTGGGGAAGTTACAGAGCACCTATATCGAAGGTTTGCTTAAAGTGGTTCACCGCGATACAAACAAGGTCCATACGATATTCAATCAAGCTCTCACTCAGACCGGCCGACTATCTTCCACAGAGCCTAACCTGCAAAATATTCCCATCCGGTTAGAAGAGGGAAGAAAAATAAGGCAGGCCTTTGTACCATCAGAACCGGACTGGGTGATTTTCTCGGCAGATTACAGTCAAATCGAGTTGCGTGTTCTTGCGCACATAGCTAACGACGAAAATCTCATTGCCGCATTTCGCCATGATCTAGACATCCACACGAAGACTGCGATGGATATATTCCATGTCAACGAGGACGAAGTAACCCCTAATATGCGACGGCAGGCTAAAGCCGTGAACTTTGGGATTGTTTATGGTATCAGCGATTACGGCCTGTCTCAAAATTTAAACATAACAAGAAAGGAGGCAGCGGAATTCATTAAAAGGTATTTTGAGATCTTCCCCGGAGTCAAGCAGTACATGAATGACATAGTACAAGAAGCTAAACAGAAGGGGTATGTGACGACTTTGCTTCACCGTCGCCGATACCTCCCAGATATTACCTCCCGGAACTTTAATCTAAGATCATTCGCCGAGAGGACAGCAATGAACACGCCGATCCAAGGTTCGGCGGCTGACATAATTAAAAAGGCCATGATCGATCTGAGTAATCGTTTAAAAAAGGAAAACATGAAAGCACGCATGTTGCTTCAGGTTCATGACGAGCTCATACTAGAAGCGCCTAAGGAGGAAATTGAGCGACTGCAACAGATCGTCCCCGAAGTAATGGAGAATGCTGTGCAATTACGGGTTCCATTGAAAGTCGATTATCACTTTGGCCCGACTTGGTACGACGCCAAG(SEQ ID NO.2)。
第二方面,本发明提供了上述Bst DNA聚合酶突变体在制备环介导等温扩增产品中的应用。
本发明提供的Bst DNA聚合酶突变体,热稳定性好,非特异性扩增反应减少,重复性好,能够应用于环介导等温扩增技术中。
第三方面,本发明提供了一种环介导等温扩增产品,包括上述Bst DNA聚合酶突变体。该环介导等温扩增产品非特异性扩增反应少,重复性好。
第四方面,本发明提供了一种基因,所述基因编码上述Bst DNA聚合酶突变体。例如该基因可以具有SEQ ID NO.2所示的核苷酸序列。
第五方面,本发明提供了一种重组质粒,所述重组质粒包括载体和上述基因。其中,载体包括但不限于pET-24a(+)质粒。
第六方面,本发明提供了一种基因工程菌,所述基因工程菌含有上述重组质粒。其中,基因工程菌例如可以为大肠杆菌BL21。
下面通过具体的实施例和对比例进一步说明本发明,但是,应当理解为,这些实施例仅仅是用于更详细地说明之用,而不应理解为用于以任何形式限制本发明。
以下实施例中所用的引物如下表所示:
表1 引物
Figure P_220425163130043_043496001
实施例1
1)对Bst DNA聚合酶进行突变的具体过程如下:本发明所述Bst DNA聚合酶是通过pET-24a(+)作为载体构建表达的,为快速准确地构建获得重组载体,并且以大肠杆菌BL21作为最终的宿主,本发明采用的Golden gate组装技术设计PCR引物。
2)具体实施如下:依据Bst DNA聚合酶的原始氨基酸序列输入到Codon Optimizer软件中同时输入大肠杆菌基因组序列信息,导出Bst DNA聚合酶对应的核酸序列SEQ IDNO.3。
3)依据Bst DNA聚合酶核酸序列设计引物Bst-F和Bst-R。
4)以本团队先前的pUC18-Bst质粒(插入有SEQ ID NO.3的pUC18)为模板,以Mut370-F/Mut370-R引物以pMD-18-Bst为模板获得Bst DNA聚合酶Met370Cys突变体,PCR反应体系设置如下:
表2 PCR反应体系
Figure P_220425163130121_121609001
反应程序:预变性95℃ 5min、变性95℃ 15s、退火58℃ 15s、延伸72℃ 20s、循环30、在延伸72℃ 5min。
5)将上述所获得的PCR产物进行琼脂糖核酸电泳,通过胶回收(ATGPure™ GelDNA Extraction Mini Kit)获得突变DNA基因片段1。
6)将上述所获得的突变DNA基因片段1于pMD-18T克隆载体按照如下体系进行TA连接。
表3 TA连接体系
Figure P_220425163130169_169932001
将上述所获得的连接产物取10 μl转化至100 μl DH5a感受态中,置于冰上冷击30min,然后42 ℃热击45 s,再置于冰上冷击5 min,加入890 μl LB培养基之后置于37℃、200rpm摇床孵育1h。4000rpm离心1min收集菌体,留100μl上清重悬之后涂布到Amp抗性的平板中,筛选出阳性克隆子。通过M13F引物与M13R引物进行菌落PCR验证,挑取阳性克隆转接测序。
7)将上述所获得的pMD-18T-Mut370重组菌株提取获取高纯度质粒,并以此为模板设计引物Mut444-F/Mut444-R对Ala444位点进行定点突变为Gly,通过菌落PCR验证、以及测序确定突变结果。
8)将测序验证突变成功的Bst DNA聚合酶重组质粒,按如下酶切体系分别切割pET-24a(+)质粒与Met370Gly和Ala444Gly位点两位点突变pMD-18T-BstMut质粒获取线性化载体pET-24a(+)以及BstMut突变DNA片段。
表4 酶切反应体系
Figure P_220425163130216_216793001
9)将上述所得的酶切产物跑琼脂糖核酸电泳,切取正确的条带用南京巨匠生物科技有限公司ATGPure™ PCR product purification kit试剂盒回收获得DNA片段。
10)将上述所获得的MutBst突变DNA片段与pET-24a载体DNA片段按照如下体系进行重组反应。
表5 重组反应体系
Figure P_220425163130248_248096001
备注:5×UFO Buffer为本公司自主研发的试剂
11)将上述所获得的重组连接产物取10 μl转化至100 μl BL21(rosseta)感受态中,置于冰上冷击30 min,然后42 ℃热击45 s,再置于冰上冷击5 min,加入890 μl LB培养基之后置于37℃、200rpm摇床孵育1h。4000rpm离心1min收集菌体,留100μl上清重悬之后涂布到Kan抗性的平板中,筛选出阳性克隆子。通过T7引物与T7terminator引物进行菌落PCR验证,挑取阳性克隆转接测序。
12)通过测序分析Met370Gly和Ala444Gly位点的突变结果。
13)对上述突变体MutBst菌株转接至3 ml LB培养过夜,次日转接至500ml LB中培养至OD600=0.6-0.8之间,加入0.5 mM IPTG在37℃条件下诱导16小时。发酵诱导表达结束后离心收集菌体,用20 mM Tris-HCl、500 mM NaCl重悬菌体,通过Ni柱亲和层析纯化获得突变的Bst DNA聚合酶。
14)将上述所获得的Bst按如下体系配置成PCR反应体系进行上机实验。
表6 PCR反应体系
Figure P_220425163130279_279334001
备注:10×Reaction Buffer为公司自主研发试剂盒中的组分。
实施例2 Mut Bst 在LAMP不同温度条件下的结果对比
结果如图2所示,按照实施例1步骤14)的PCR反应体系,对突变体Bst进行不同温度的四组重复试验,即65℃、72℃、75℃、80℃四个水平,对不同温度反应30min下的PCR反应产物进行核酸电泳。在65℃以上的扩增效果均达到测试要求,对于温度的耐受性也有所提高。
实施例3 BstMut在RT-LAMP扩增中的使用
将纯化得到的Bst蛋白酶夜配置成如下体系测试RT-LAMP扩增效果。
1.PCR 管中配制引物混合液primer Mix。
表7 引物混合液primer Mix
Figure P_220425163130343_343241001
2.qPCR 管中配置如下混合液。
表8 扩增反应体系
Figure P_220425163130390_390654001
备注:上述实验组分来自于南京巨匠生物自主研发的试剂盒,具体使用详情请参考官网。
对上述RT-LAMP实验中以80℃作为扩增温度,然后80℃、30min下的进行PCR扩增反应,结果如图3所示。
同时再对比RT-LAMP实验中80℃温度条件下的对照组无扩增,说明突变体Bst的温度稳定性有显著提升。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
SEQUENCE LISTING
<110> 南京巨匠生物科技有限公司
<120> Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌
<160> 13
<170> PatentIn version 3.5
<210> 1
<211> 876
<212> PRT
<213> 人工序列
<400> 1
Met Lys Lys Lys Leu Val Leu Ile Asp Gly Asn Ser Val Ala Tyr Arg
1 5 10 15
Ala Phe Phe Ala Leu Pro Leu Leu His Asn Asp Lys Gly Ile His Thr
20 25 30
Asn Ala Val Tyr Gly Phe Thr Met Met Leu Asn Lys Ile Leu Ala Glu
35 40 45
Glu Gln Pro Thr His Leu Leu Val Ala Phe Asp Ala Gly Lys Thr Thr
50 55 60
Phe Arg His Glu Thr Phe Gln Glu Tyr Lys Gly Gly Arg Gln Gln Thr
65 70 75 80
Pro Pro Glu Leu Ser Glu Gln Phe Pro Leu Leu Arg Glu Leu Leu Lys
85 90 95
Ala Tyr Arg Ile Pro Ala Tyr Glu Leu Asp His Tyr Glu Ala Asp Asp
100 105 110
Ile Ile Gly Thr Leu Ala Ala Arg Ala Glu Gln Glu Gly Phe Glu Val
115 120 125
Lys Ile Ile Ser Gly Asp Arg Asp Leu Thr Gln Leu Ala Ser Arg His
130 135 140
Val Thr Val Asp Ile Thr Lys Lys Gly Ile Thr Asp Ile Glu Pro Tyr
145 150 155 160
Thr Pro Glu Thr Val Arg Glu Lys Tyr Gly Leu Thr Pro Glu Gln Ile
165 170 175
Val Asp Leu Lys Gly Leu Met Gly Asp Lys Ser Asp Asn Ile Pro Gly
180 185 190
Val Pro Gly Ile Gly Glu Lys Thr Ala Val Lys Leu Leu Lys Gln Phe
195 200 205
Gly Thr Val Glu Asn Val Leu Ala Ser Ile Asp Glu Val Lys Gly Glu
210 215 220
Lys Leu Lys Glu Asn Leu Arg Gln His Arg Asp Leu Ala Leu Leu Ser
225 230 235 240
Lys Gln Leu Ala Ser Ile Cys Arg Asp Ala Pro Val Glu Leu Ser Leu
245 250 255
Asp Asp Ile Val Tyr Glu Gly Gln Asp Arg Glu Lys Val Ile Ala Leu
260 265 270
Phe Lys Glu Leu Gly Phe Gln Ser Phe Leu Glu Lys Met Ala Ala Pro
275 280 285
Ala Ala Glu Gly Glu Lys Pro Leu Glu Glu Met Glu Phe Ala Ile Val
290 295 300
Asp Val Ile Thr Glu Glu Met Leu Ala Asp Lys Ala Ala Leu Val Val
305 310 315 320
Glu Val Met Glu Glu Asn Tyr His Asp Ala Pro Ile Val Gly Ile Ala
325 330 335
Leu Val Asn Glu His Gly Arg Phe Phe Met Arg Pro Glu Thr Ala Leu
340 345 350
Ala Asp Ser Gln Phe Leu Ala Trp Leu Ala Asp Glu Thr Lys Lys Lys
355 360 365
Ser Gly Phe Asp Ala Lys Arg Ala Val Val Ala Leu Lys Trp Lys Gly
370 375 380
Ile Glu Leu Arg Gly Val Ala Phe Asp Leu Leu Leu Ala Ala Tyr Leu
385 390 395 400
Leu Asn Pro Ala Gln Asp Ala Gly Asp Ile Ala Ala Val Ala Lys Met
405 410 415
Lys Gln Tyr Glu Ala Val Arg Ser Asp Glu Ala Val Tyr Gly Lys Gly
420 425 430
Val Lys Arg Ser Leu Pro Asp Glu Gln Thr Leu Gly Glu His Leu Val
435 440 445
Arg Lys Ala Ala Ala Ile Trp Ala Leu Glu Gln Pro Phe Met Asp Asp
450 455 460
Leu Arg Asn Asn Glu Gln Asp Gln Leu Leu Thr Lys Leu Glu Gln Pro
465 470 475 480
Leu Ala Ala Ile Leu Ala Glu Met Glu Phe Thr Gly Val Asn Val Asp
485 490 495
Thr Lys Arg Leu Glu Gln Met Gly Ser Glu Leu Ala Glu Gln Leu Arg
500 505 510
Ala Ile Glu Gln Arg Ile Tyr Glu Leu Ala Gly Gln Glu Phe Asn Ile
515 520 525
Asn Ser Pro Lys Gln Leu Gly Val Ile Leu Phe Glu Lys Leu Gln Leu
530 535 540
Pro Val Leu Lys Lys Thr Lys Thr Gly Tyr Ser Thr Ser Ala Asp Val
545 550 555 560
Leu Glu Lys Leu Ala Pro His His Glu Ile Val Glu Asn Ile Leu His
565 570 575
Tyr Arg Gln Leu Gly Lys Leu Gln Ser Thr Tyr Ile Glu Gly Leu Leu
580 585 590
Lys Val Val Arg Pro Asp Thr Gly Lys Val His Thr Met Phe Asn Gln
595 600 605
Ala Leu Thr Gln Thr Gly Arg Leu Ser Ser Ala Glu Pro Asn Leu Gln
610 615 620
Asn Ile Pro Ile Arg Leu Glu Glu Gly Arg Lys Ile Arg Gln Ala Phe
625 630 635 640
Val Pro Ser Glu Pro Asp Trp Leu Ile Phe Ala Ala Asp Tyr Ser Gln
645 650 655
Ile Glu Leu Arg Val Leu Ala His Ile Ala Asp Asp Asp Asn Leu Ile
660 665 670
Glu Ala Phe Gln Arg Asp Leu Asp Ile His Thr Lys Thr Ala Met Asp
675 680 685
Ile Phe His Val Ser Glu Glu Glu Val Thr Ala Asn Met Arg Arg Gln
690 695 700
Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp Tyr Gly
705 710 715 720
Leu Ala Gln Asn Leu Asn Ile Thr Arg Lys Glu Ala Ala Glu Phe Ile
725 730 735
Glu Arg Tyr Phe Ala Ser Phe Pro Gly Val Lys Gln Tyr Met Glu Asn
740 745 750
Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu Leu His
755 760 765
Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn Val Arg
770 775 780
Ser Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly Ser Ala
785 790 795 800
Ala Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ala Ala Arg Leu Lys
805 810 815
Glu Glu Gln Leu Gln Ala Arg Leu Leu Leu Gln Val His Asp Glu Leu
820 825 830
Ile Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Glu Leu Val
835 840 845
Pro Glu Val Met Glu Gln Ala Val Thr Leu Arg Val Pro Leu Lys Val
850 855 860
Asp Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys
865 870 875
<210> 2
<211> 2631
<212> DNA
<213> 人工序列
<400> 2
atgaaaaaga aattagtttt gattgatggt aattctgtcg cttatcgtgc ctttttcgca 60
cttcctctcc tacattccga caagggcatc cacactaacg cggtatacgg atttaccatg 120
atgctgatga aaatattaga agaggaaaag cccacacata tgttggtggc tttcgatgcc 180
gggaaaacga cttttcgcca caagaccttc gaggaatata aaggtggccg acaaaagaca 240
ccaccggagc tttcagaaca gtttcctctc ctacgggagc tgttaaatgc ataccaaatt 300
agattctatg aattggagaa ctacgaagcg gacgatatca taggaacgct ttgtactaaa 360
gctgagaatg ccgggtttga agttaaggtc atttcgggtg acagggatct cacccagcta 420
gcaagtgacc atgtaacagt ggatatcacg aaaaagggca taactgacgt tgagagctat 480
acccccgaaa cagtccgtga gaaatacgga ctgacgccaa agcaaattat cgatttaaaa 540
gggttgatgg gtgacaagtc tgataacata ccgggcgtac ctggaattgg ggaaaaaact 600
gcgcttaagc tcctaaaaga gttcggtacc atcgaaaata tactggactc cttagagcag 660
atttcaggca acaagttgaa agaaaatctt gctaagtatc gcgatctcgc catcatgtcg 720
aaacaactag caacaatact gcgagacgcg cccattgatt taagtttgga ggacatcgaa 780
taccggggat atgatgctga caaggtgata gcccttttta aagagctcgg gttcaacagc 840
ctactggata agatggcacc aagagaagag gaaaaagcgg gtgttgtctt accgaagatt 900
ggctacacga tcgtagacga ggtgactgaa gctatattgt ctgatgaggc cgcacttgtt 960
gtcgaagtac tcgagtccaa ttatcacaaa gcgcctattc taggatttgc tatcgccaac 1020
gaacatggga atttctttat aaggaccgac acagcactgt catcgagttt attcacggcg 1080
tggttggagg atgaaagcaa gaaaaagggt gtgtttgacg gtaaacgtgc tattgtttcc 1140
cttaagtggc agggcgtcca actccgcgga atccagttcg atctactgat agcctcatac 1200
ttattgaacc cctcgcaaag tactgaggac gtagcaagca ttgcgaaaac caagcagtat 1260
acaggggtgc aaccagatga agctgtttac ggtaaaggcg ccaagcagaa aatcccggac 1320
gagcaagtcc ttggagaaca cctcgtacga aaggcggctg ccatacgggc actagagcag 1380
gattttattc atgacctgca agaaaatgag cagtattctt tattcacgga tttggaactt 1440
cctctctccg cgatcctagc tgagatggaa tttactggag tgaaagttga cgtcaagaga 1500
ctgaaagaga tgggggaaga gttaaccgaa caattgaagg aggtagaaca ggagatatac 1560
aggcttgccg gtcaagaatt caacattaat tcacccaaac agctcggcgt gatcctattt 1620
gagaagctgc aattaccagt tttgaaaaag acaaaaacgg gatattcgac tagtgcagaa 1680
gtccttgaga agctcgcgcc gcagcacgaa atagtagaga aaattctaca ttaccgtcaa 1740
ctggggaagt tacagagcac ctatatcgaa ggtttgctta aagtggttca ccgcgataca 1800
aacaaggtcc atacgatatt caatcaagct ctcactcaga ccggccgact atcttccaca 1860
gagcctaacc tgcaaaatat tcccatccgg ttagaagagg gaagaaaaat aaggcaggcc 1920
tttgtaccat cagaaccgga ctgggtgatt ttctcggcag attacagtca aatcgagttg 1980
cgtgttcttg cgcacatagc taacgacgaa aatctcattg ccgcatttcg ccatgatcta 2040
gacatccaca cgaagactgc gatggatata ttccatgtca acgaggacga agtaacccct 2100
aatatgcgac ggcaggctaa agccgtgaac tttgggattg tttatggtat cagcgattac 2160
ggcctgtctc aaaatttaaa cataacaaga aaggaggcag cggaattcat taaaaggtat 2220
tttgagatct tccccggagt caagcagtac atgaatgaca tagtacaaga agctaaacag 2280
aaggggtatg tgacgacttt gcttcaccgt cgccgatacc tcccagatat tacctcccgg 2340
aactttaatc taagatcatt cgccgagagg acagcaatga acacgccgat ccaaggttcg 2400
gcggctgaca taattaaaaa ggccatgatc gatctgagta atcgtttaaa aaaggaaaac 2460
atgaaagcac gcatgttgct tcaggttcat gacgagctca tactagaagc gcctaaggag 2520
gaaattgagc gactgcaaca gatcgtcccc gaagtaatgg agaatgctgt gcaattacgg 2580
gttccattga aagtcgatta tcactttggc ccgacttggt acgacgccaa g 2631
<210> 3
<211> 876
<212> PRT
<213> 人工序列
<400> 3
Met Lys Lys Lys Leu Val Leu Ile Asp Gly Asn Ser Val Ala Tyr Arg
1 5 10 15
Ala Phe Phe Ala Leu Pro Leu Leu His Asn Asp Lys Gly Ile His Thr
20 25 30
Asn Ala Val Tyr Gly Phe Thr Met Met Leu Asn Lys Ile Leu Ala Glu
35 40 45
Glu Gln Pro Thr His Leu Leu Val Ala Phe Asp Ala Gly Lys Thr Thr
50 55 60
Phe Arg His Glu Thr Phe Gln Glu Tyr Lys Gly Gly Arg Gln Gln Thr
65 70 75 80
Pro Pro Glu Leu Ser Glu Gln Phe Pro Leu Leu Arg Glu Leu Leu Lys
85 90 95
Ala Tyr Arg Ile Pro Ala Tyr Glu Leu Asp His Tyr Glu Ala Asp Asp
100 105 110
Ile Ile Gly Thr Leu Ala Ala Arg Ala Glu Gln Glu Gly Phe Glu Val
115 120 125
Lys Ile Ile Ser Gly Asp Arg Asp Leu Thr Gln Leu Ala Ser Arg His
130 135 140
Val Thr Val Asp Ile Thr Lys Lys Gly Ile Thr Asp Ile Glu Pro Tyr
145 150 155 160
Thr Pro Glu Thr Val Arg Glu Lys Tyr Gly Leu Thr Pro Glu Gln Ile
165 170 175
Val Asp Leu Lys Gly Leu Met Gly Asp Lys Ser Asp Asn Ile Pro Gly
180 185 190
Val Pro Gly Ile Gly Glu Lys Thr Ala Val Lys Leu Leu Lys Gln Phe
195 200 205
Gly Thr Val Glu Asn Val Leu Ala Ser Ile Asp Glu Val Lys Gly Glu
210 215 220
Lys Leu Lys Glu Asn Leu Arg Gln His Arg Asp Leu Ala Leu Leu Ser
225 230 235 240
Lys Gln Leu Ala Ser Ile Cys Arg Asp Ala Pro Val Glu Leu Ser Leu
245 250 255
Asp Asp Ile Val Tyr Glu Gly Gln Asp Arg Glu Lys Val Ile Ala Leu
260 265 270
Phe Lys Glu Leu Gly Phe Gln Ser Phe Leu Glu Lys Met Ala Ala Pro
275 280 285
Ala Ala Glu Gly Glu Lys Pro Leu Glu Glu Met Glu Phe Ala Ile Val
290 295 300
Asp Val Ile Thr Glu Glu Met Leu Ala Asp Lys Ala Ala Leu Val Val
305 310 315 320
Glu Val Met Glu Glu Asn Tyr His Asp Ala Pro Ile Val Gly Ile Ala
325 330 335
Leu Val Asn Glu His Gly Arg Phe Phe Met Arg Pro Glu Thr Ala Leu
340 345 350
Ala Asp Ser Gln Phe Leu Ala Trp Leu Ala Asp Glu Thr Lys Lys Lys
355 360 365
Ser Met Phe Asp Ala Lys Arg Ala Val Val Ala Leu Lys Trp Lys Gly
370 375 380
Ile Glu Leu Arg Gly Val Ala Phe Asp Leu Leu Leu Ala Ala Tyr Leu
385 390 395 400
Leu Asn Pro Ala Gln Asp Ala Gly Asp Ile Ala Ala Val Ala Lys Met
405 410 415
Lys Gln Tyr Glu Ala Val Arg Ser Asp Glu Ala Val Tyr Gly Lys Gly
420 425 430
Val Lys Arg Ser Leu Pro Asp Glu Gln Thr Leu Ala Glu His Leu Val
435 440 445
Arg Lys Ala Ala Ala Ile Trp Ala Leu Glu Gln Pro Phe Met Asp Asp
450 455 460
Leu Arg Asn Asn Glu Gln Asp Gln Leu Leu Thr Lys Leu Glu Gln Pro
465 470 475 480
Leu Ala Ala Ile Leu Ala Glu Met Glu Phe Thr Gly Val Asn Val Asp
485 490 495
Thr Lys Arg Leu Glu Gln Met Gly Ser Glu Leu Ala Glu Gln Leu Arg
500 505 510
Ala Ile Glu Gln Arg Ile Tyr Glu Leu Ala Gly Gln Glu Phe Asn Ile
515 520 525
Asn Ser Pro Lys Gln Leu Gly Val Ile Leu Phe Glu Lys Leu Gln Leu
530 535 540
Pro Val Leu Lys Lys Thr Lys Thr Gly Tyr Ser Thr Ser Ala Asp Val
545 550 555 560
Leu Glu Lys Leu Ala Pro His His Glu Ile Val Glu Asn Ile Leu His
565 570 575
Tyr Arg Gln Leu Gly Lys Leu Gln Ser Thr Tyr Ile Glu Gly Leu Leu
580 585 590
Lys Val Val Arg Pro Asp Thr Gly Lys Val His Thr Met Phe Asn Gln
595 600 605
Ala Leu Thr Gln Thr Gly Arg Leu Ser Ser Ala Glu Pro Asn Leu Gln
610 615 620
Asn Ile Pro Ile Arg Leu Glu Glu Gly Arg Lys Ile Arg Gln Ala Phe
625 630 635 640
Val Pro Ser Glu Pro Asp Trp Leu Ile Phe Ala Ala Asp Tyr Ser Gln
645 650 655
Ile Glu Leu Arg Val Leu Ala His Ile Ala Asp Asp Asp Asn Leu Ile
660 665 670
Glu Ala Phe Gln Arg Asp Leu Asp Ile His Thr Lys Thr Ala Met Asp
675 680 685
Ile Phe His Val Ser Glu Glu Glu Val Thr Ala Asn Met Arg Arg Gln
690 695 700
Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp Tyr Gly
705 710 715 720
Leu Ala Gln Asn Leu Asn Ile Thr Arg Lys Glu Ala Ala Glu Phe Ile
725 730 735
Glu Arg Tyr Phe Ala Ser Phe Pro Gly Val Lys Gln Tyr Met Glu Asn
740 745 750
Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu Leu His
755 760 765
Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn Val Arg
770 775 780
Ser Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly Ser Ala
785 790 795 800
Ala Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ala Ala Arg Leu Lys
805 810 815
Glu Glu Gln Leu Gln Ala Arg Leu Leu Leu Gln Val His Asp Glu Leu
820 825 830
Ile Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Glu Leu Val
835 840 845
Pro Glu Val Met Glu Gln Ala Val Thr Leu Arg Val Pro Leu Lys Val
850 855 860
Asp Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys
865 870 875
<210> 4
<211> 39
<212> DNA
<213> 人工序列
<400> 4
atgaaaaaga aattagtttt gattgatggt aattctgtc 39
<210> 5
<211> 23
<212> DNA
<213> 人工序列
<400> 5
cttggcgtcg taccaagtcg ggc 23
<210> 6
<211> 24
<212> DNA
<213> 人工序列
<400> 6
gcaagaaaaa gggtgtgttt gacg 24
<210> 7
<211> 24
<212> DNA
<213> 人工序列
<400> 7
cgtcaaacac accctttttc ttgc 24
<210> 8
<211> 18
<212> DNA
<213> 人工序列
<400> 8
caggaaacag ctatgacc 18
<210> 9
<211> 18
<212> DNA
<213> 人工序列
<400> 9
tgtaaaacga cggccagt 18
<210> 10
<211> 30
<212> DNA
<213> 人工序列
<400> 10
cgagcaagtc cttggagaac acctcgtacg 30
<210> 11
<211> 30
<212> DNA
<213> 人工序列
<400> 11
cgtacgaggt gttctccaag gacttgctcg 30
<210> 12
<211> 20
<212> DNA
<213> 人工序列
<400> 12
taatacgact cactataggg 20
<210> 13
<211> 20
<212> DNA
<213> 人工序列
<400> 13
acatccactt tgcctttctc 20

Claims (10)

1.一种Bst DNA聚合酶突变体,其特征在于,所述Bst DNA聚合酶突变体的氨基酸序列如SEQ ID NO.1所示。
2.根据权利要求1所述的Bst DNA聚合酶突变体,其特征在于,所述Bst DNA聚合酶突变体的核苷酸序列如SEQ ID NO.2所示。
3.权利要求1或2所述的Bst DNA聚合酶突变体在制备环介导等温扩增产品中的应用。
4.一种环介导等温扩增产品,其特征在于,包括权利要求1或2所述的Bst DNA聚合酶突变体。
5.一种基因,其特征在于,所述基因编码权利要求1或2所述的Bst DNA聚合酶突变体。
6.根据权利要求5所述的基因,其特征在于,所述基因具有SEQ ID NO.2所示的核苷酸序列。
7.一种重组质粒,其特征在于,所述重组质粒包括载体和权利要求5或6所述的基因。
8.根据权利要求7所述的重组质粒,其特征在于,所述载体包括pET-24a(+)质粒。
9.一种基因工程菌,其特征在于,所述基因工程菌含有权利要求7或8所述的重组质粒。
10.根据权利要求9所述的基因工程菌,其特征在于,所述基因工程菌包括大肠杆菌。
CN202210447410.5A 2022-04-27 2022-04-27 Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌 Active CN114561372B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210447410.5A CN114561372B (zh) 2022-04-27 2022-04-27 Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210447410.5A CN114561372B (zh) 2022-04-27 2022-04-27 Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌

Publications (2)

Publication Number Publication Date
CN114561372A CN114561372A (zh) 2022-05-31
CN114561372B true CN114561372B (zh) 2022-07-26

Family

ID=81720762

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210447410.5A Active CN114561372B (zh) 2022-04-27 2022-04-27 Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌

Country Status (1)

Country Link
CN (1) CN114561372B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115975978B (zh) * 2023-02-01 2023-08-01 珠海宝锐生物科技有限公司 Bst DNA聚合酶大片段突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0901593D0 (en) * 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
CN114369586B (zh) * 2022-03-21 2022-06-07 南京巨匠生物科技有限公司 Taq DNA聚合酶突变体及其应用和产品、基因、质粒和基因工程菌

Also Published As

Publication number Publication date
CN114561372A (zh) 2022-05-31

Similar Documents

Publication Publication Date Title
KR20110044753A (ko) 기능 개선된 rna 중합효소 변이체
JP2003510052A (ja) 改良されたポリヌクレオチド合成のための方法と組成物
CN113862233B (zh) 提高葡萄糖氧化酶的酸稳定性的方法及突变体q241e/r499e、基因和应用
JP4486009B2 (ja) Dnaリガーゼ変異体
CN114561372B (zh) Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌
JP2863738B2 (ja) 熱安定性ピロホスファターゼをコードするdna
KR20220083647A (ko) 신규 과당-4-에피머화 효소 및 이를 이용한 타가토스의 제조 방법
CN114561374A (zh) 一种新型嗜热核酸内切酶突变体及其制备方法和应用
JP7014256B2 (ja) 核酸増幅試薬
CN112029744A (zh) Dna聚合酶及其编码基因、制备方法和pcr应用
KR102409878B1 (ko) 신규 과당-4-에피머화 효소 및 이를 이용한 타가토스의 제조 방법
WO2007117331A2 (en) Novel dna polymerase from thermoanaerobacter tengcongenesis
JP4399684B2 (ja) 改良されたrnaポリメラーゼ
CN114574464B (zh) 高保真dna聚合酶突变体及其应用
CN114480345B (zh) MazF突变体、重组载体、重组工程菌及其应用
CN109943549A (zh) 一种超高速扩增型Taq DNA聚合酶
WO2023082266A1 (zh) 嵌合dna聚合酶及其应用
CN112899255B (zh) Dna聚合酶及其应用、重组载体及其制备方法和应用、重组工程菌及其应用
CN116410952A (zh) 突变型Taq DNA聚合酶、编码基因、重组表达载体、重组菌及其应用
CN113564141B (zh) 单细胞基因组扩增酶突变体及其应用
CN114250206B (zh) 甲基转移酶突变体、重组载体、重组工程菌及其应用
CN114752572B (zh) 甲酸脱氢酶突变体及其应用
KR100969477B1 (ko) 써모코커스 구아이마센시스 균주 유래 내열성 dna중합효소 및 이를 이용한 중합효소 연쇄반응 방법
CN117467640A (zh) 突变型Taq DNA聚合酶及其应用
CN114958797A (zh) 突变型dna聚合酶、编码基因、重组表达载体、重组菌及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant